Operating Profit Margin
since 2012
Calculation
AbbVie Inc., operating profit margin, long-term trends, calculation
| Operating profit margin | = | 100 | × | Operating earnings1 | ÷ | Net revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | 23.49% | = | 100 | × | 12,757) | ÷ | 54,318) |
| Dec 31, 2022 | 31.21% | = | 100 | × | 18,117) | ÷ | 58,054) |
| Dec 31, 2021 | 31.89% | = | 100 | × | 17,924) | ÷ | 56,197) |
| Dec 31, 2020 | 24.81% | = | 100 | × | 11,363) | ÷ | 45,804) |
| Dec 31, 2019 | 39.03% | = | 100 | × | 12,983) | ÷ | 33,266) |
| Dec 31, 2018 | 19.49% | = | 100 | × | 6,383) | ÷ | 32,753) |
| Dec 31, 2017 | 33.99% | = | 100 | × | 9,592) | ÷ | 28,216) |
| Dec 31, 2016 | 36.60% | = | 100 | × | 9,384) | ÷ | 25,638) |
| Dec 31, 2015 | 32.97% | = | 100 | × | 7,537) | ÷ | 22,859) |
| Dec 31, 2014 | 17.09% | = | 100 | × | 3,411) | ÷ | 19,960) |
| Dec 31, 2013 | 30.14% | = | 100 | × | 5,664) | ÷ | 18,790) |
| Dec 31, 2012 | 31.65% | = | 100 | × | 5,817) | ÷ | 18,380) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$ in millions
Comparison to Competitors
AbbVie Inc., operating profit margin, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | 23.49% | 29.35% | 21.77% | 28.24% | 30.85% | 16.00% | 38.83% |
| Dec 31, 2022 | 31.21% | 38.57% | 27.61% | 27.17% | 38.93% | 18.69% | 48.23% |
| Dec 31, 2021 | 31.89% | 31.44% | 25.35% | 36.72% | 55.67% | 25.57% | 36.73% |
| Dec 31, 2020 | 24.81% | 37.70% | 18.99% | 16.72% | 42.09% | 24.19% | 46.03% |
| Dec 31, 2019 | 39.03% | 43.57% | 18.25% | 19.38% | 28.10% | 17.99% | 28.77% |
| Dec 31, 2018 | 19.49% | 45.55% | 17.11% | 37.83% | 37.77% | 15.53% | 20.84% |
| Dec 31, 2017 | 33.99% | 45.76% | 16.48% | 55.04% | 35.41% | 14.19% | 4.95% |
| Dec 31, 2016 | 36.60% | 44.74% | 16.29% | 58.87% | 27.38% | 13.40% | 0.58% |
| Dec 31, 2015 | 32.97% | 40.44% | 16.87% | 69.03% | 30.51% | 13.77% | -45.23% |
| Dec 31, 2014 | 17.09% | 32.03% | 17.23% | 62.37% | 29.74% | 14.82% | -119.30% |
| Dec 31, 2013 | 30.14% | 32.25% | 17.13% | 41.87% | 36.11% | 12.30% | -74.54% |
| Dec 31, 2012 | 31.65% | 33.52% | 17.33% | 42.67% | 33.20% | 11.85% | 0.15% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).